×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023
PR Newswire
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver...
1 month ago
Five companies racing to bring their NASH treatments toward the finish line
Labiotech.eu
NASH is a severe form of non-alcoholic fatty liver disease (NAFLD), where fat builds up on the liver, potentially leading to liver damage or...
4 months ago
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
PR Newswire
The Letter has no immediate effect on the Company's Nasdaq listing or the trading of its ordinary shares, and during the grace period, as may be...
7 months ago
NASH on the Cusp: An Emerging Market Opportunity
BioSpace
The non-alcoholic steatohepatitis space is still a “big mystery,” analysts tell BioSpace, but its connection to weight loss could provide an...
6 months ago
Galmed employs AI models to help with PSC trial enrolment
Clinical Trials Arena
Galmed will use OnKai's AI models to find the right patients for its upcoming Phase IIa trial in a rare liver disease.
10 months ago
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering
PR Newswire
TEL AVIV, Israel, July 14, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. ... The gross proceeds of the Offering to the Company, before...
10 months ago
Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?
Yahoo Finance
A company's cash runway is calculated by dividing its cash hoard by its cash burn. In September 2022, Galmed Pharmaceuticals had US$19m in cash,...
16 months ago
Financial Adviser Sues Pharma Biz Over Merger Fees
Law360
Financial adviser Strand Hanson has sued Conduit Pharmaceuticals for allegedly unpaid fees stemming from a $720 million merger after...
7 months ago
Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?
Simply Wall Street
While Galmed Pharmaceuticals is showing a solid reduction in its cash burn, it's still worth considering how easily it could raise more cash,...
11 months ago
Questionable data aside, Galmed Pharma soars in a fatty liver stock bubble
STAT
The Aramchol clinical data in NASH were more miss than hit, benefiting from the company's decision to highlight certain clinical endpoints...
71 months ago